Status:
COMPLETED
Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
This study will last up to 3 years. You will visit the clinic up to 14 times. Certain visits will include lung function tests and scans of your bones. The purpose of this study is to determine the eff...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Established clinical history of COPD.
- Baseline FEV1 \<70% predicted normal, and FEV1/FVC ratio of less than 70%.
- Smoking history of at least 10 pack-years, where both current and former smokers will be eligible.
- Must have at least one native, evaluable hip.
- Exclusion criteria:
- History of or evidence for metabolic bone diseases other than osteoporosis or osteopenia.
Exclusion
Key Trial Info
Start Date :
April 28 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 6 2007
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT00355342
Start Date
April 28 2004
End Date
September 6 2007
Last Update
July 2 2018
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Berkeley, California, United States, 94705
2
GSK Investigational Site
Fullerton, California, United States, 92835
3
GSK Investigational Site
Rancho Mirage, California, United States, 92270
4
GSK Investigational Site
San Diego, California, United States, 92103